Abstract
Because of its low positron energy, lack of side emission, and a moderate half-life, Fluorine-18 (β+, 0.635 MeV [97%], t1/2 = 109.8 min) has ideal physical properties for positron emission tomography (PET). With the increasing numbers of peptides that are potentially applicable for molecular imaging of diseases, novel and simple 18F-labeling methods have been actively investigated and reported. In this review, a few well established and widely-used radiofluorination strategies are discussed. Novel approaches including click chemistry, one-step chelation labeling (i.e. Al18F-NOTA), and silicon-based 18F labeling are described as well.
Keywords: 18F, Radiofluorination, Positron emission tomography, Peptide, Molecular Imaging, SPECT, chelation labeling, click reaction, HPLC
Current Organic Synthesis
Title: Recent Progress in Radiofluorination of Peptides for PET Molecular Imaging
Volume: 8 Issue: 4
Author(s): Shuanglong Liu, Bin Shen, Frederick T. Chin and Zhen Cheng
Affiliation:
Keywords: 18F, Radiofluorination, Positron emission tomography, Peptide, Molecular Imaging, SPECT, chelation labeling, click reaction, HPLC
Abstract: Because of its low positron energy, lack of side emission, and a moderate half-life, Fluorine-18 (β+, 0.635 MeV [97%], t1/2 = 109.8 min) has ideal physical properties for positron emission tomography (PET). With the increasing numbers of peptides that are potentially applicable for molecular imaging of diseases, novel and simple 18F-labeling methods have been actively investigated and reported. In this review, a few well established and widely-used radiofluorination strategies are discussed. Novel approaches including click chemistry, one-step chelation labeling (i.e. Al18F-NOTA), and silicon-based 18F labeling are described as well.
Export Options
About this article
Cite this article as:
Liu Shuanglong, Shen Bin, T. Chin Frederick and Cheng Zhen, Recent Progress in Radiofluorination of Peptides for PET Molecular Imaging, Current Organic Synthesis 2011; 8 (4) . https://dx.doi.org/10.2174/157017911796117197
DOI https://dx.doi.org/10.2174/157017911796117197 |
Print ISSN 1570-1794 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6271 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Detection of Tumor Markers with ProteinChip® Technology
Current Pharmaceutical Biotechnology A Systemic Approach to Cancer Treatment: Tumor Cell Reprogramming Focused on Endocrine-Related Cancers
Current Medicinal Chemistry Perspectives on Medicinal Properties of Benzoquinone Compounds
Mini-Reviews in Medicinal Chemistry Interaction between Microbes and Host Intestinal Health: Modulation by Dietary Nutrients and Gut-Brain-Endocrine-Immune Axis
Current Protein & Peptide Science Biology of Cox-2: An Application in Cancer Therapeutics
Current Drug Targets Anticipation in Lynch Syndrome: Where We Are Where We Go
Current Genomics Structure Based Lead Optimization Approach in Discovery of Selective DPP4 Inhibitors
Mini-Reviews in Medicinal Chemistry Transplantation of Pancreatic Islets Immobilized in Alginate-Based Microcapsules: From Animal Studies to Clinical Trials
Micro and Nanosystems Studies on Anticancer Activities of Lactoferrin and Lactoferricin
Current Protein & Peptide Science Strategies Targeting DNA Topoisomerase I in Cancer Chemotherapy: Camptothecins, Nanocarriers for Camptothecins, Organic Non-Camptothecin Compounds and Metal Complexes
Current Drug Targets Antidiabetics: Structural Diversity of Molecules with a Common Aim
Current Medicinal Chemistry The Role of Lymphotoxin Receptor Signaling in Diseases
Current Molecular Medicine Does Phosphodiesterase 11A (PDE11A) Hold Promise as a Future Therapeutic Target?
Current Pharmaceutical Design The Holy Grail of Polymer Therapeutics for Cancer Therapy: An Overview on the Pharmacokinetics and Bio Distribution
Current Drug Metabolism Immunotherapy for Prostate Cancer
Current Pharmaceutical Design Insulin Therapy for Diabetes Epidemic: A Patent Review
Current Drug Delivery A Structural Insight into Hydroxamic Acid Based Histone Deacetylase Inhibitors for the Presence of Anticancer Activity
Current Medicinal Chemistry Diabetic Complications: An Update on Pathobiology and Therapeutic Strategies
Current Diabetes Reviews Poly(ADP-Ribose) Polymerases in Aging – Friend or Foe?
Current Protein & Peptide Science Recent Patents Reveal Microtubules as Persistent Promising Target for Novel Drug Development for Cancers
Recent Patents on Anti-Infective Drug Discovery